Other than the slightly higher proportion of patients in the epoetin group with ovarian carcinoma as a result of the three arm design of the study by ten Bokkel Huinink et al (1998), no clinically relevant differences between the groups were noted. This evidence concerns the gene EPO and ovarian carcinoma.